Northstar Group Inc. boosted its stake in Davita Inc (NYSE:DVA) by 7.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,684 shares of the company’s stock after buying an additional 850 shares during the quarter. Northstar Group Inc.’s holdings in Davita were worth $837,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of the stock. OppenheimerFunds Inc. lifted its stake in Davita by 58.7% in the 2nd quarter. OppenheimerFunds Inc. now owns 4,066,317 shares of the company’s stock valued at $282,365,000 after buying an additional 1,504,347 shares in the last quarter. Boston Partners lifted its stake in shares of Davita by 5.0% during the 2nd quarter. Boston Partners now owns 2,137,616 shares of the company’s stock worth $148,436,000 after purchasing an additional 101,558 shares during the period. Orbimed Advisors LLC lifted its stake in shares of Davita by 8.3% during the 2nd quarter. Orbimed Advisors LLC now owns 1,689,400 shares of the company’s stock worth $117,312,000 after purchasing an additional 129,800 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Davita by 3.0% during the 2nd quarter. Janus Henderson Group PLC now owns 1,284,092 shares of the company’s stock worth $89,168,000 after purchasing an additional 37,362 shares during the period. Finally, Investec Asset Management LTD lifted its stake in shares of Davita by 114.5% during the 2nd quarter. Investec Asset Management LTD now owns 986,777 shares of the company’s stock worth $68,522,000 after purchasing an additional 526,847 shares during the period. 87.50% of the stock is currently owned by hedge funds and other institutional investors.
DVA has been the topic of a number of recent analyst reports. Zacks Investment Research raised Davita from a “hold” rating to a “buy” rating and set a $78.00 price target on the stock in a research note on Monday, July 9th. JPMorgan Chase & Co. raised Davita from an “underweight” rating to a “neutral” rating in a research note on Thursday, September 13th. Finally, ValuEngine raised Davita from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Six analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Davita has an average rating of “Buy” and an average target price of $82.50.
Davita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, August 1st. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.88 billion. Davita had a return on equity of 14.49% and a net margin of 4.30%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.92 EPS. Equities research analysts anticipate that Davita Inc will post 4 EPS for the current year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.